Dr. Ari S. Kellen, M.D. – Director
Medical Doctor, University of Witwatersrand | MBA, University of Witwatersrand
Dr. Ari Kellen is a seasoned senior executive with over three decades of healthcare industry experience, both in management consulting and in major global P&L operational roles. Dr. Kellen trained and worked as a physician in South Africa while also running a large segment of a 1,000 bed teaching hospital. After being recruited by McKinsey & Company, he spent 23 years serving healthcare clients around the world. Dr. Kellen served for more than a decade as a Senior Partner at McKinsey, advising CEOs and Board members at large industry-leading healthcare companies and small rapidly growing entities. His experience spans biotechnology, medical device, payor and provider organizations, and includes work focused on M&A, business development, new company spin-outs, corporate and business unit level turnarounds, R&D portfolio strategy, and product / therapeutic area growth strategies. In 2014, Dr. Kellen was recruited to Bausch + Lomb / Valeant where he ran a multi-billion dollar P&L across the US and Latin America. As EVP and General Manager of US Bausch + Lomb, he successfully launched and commercialized new products in Pharmaceuticals, Surgical, and Vision Care / Contact Lenses. Dr. Kellen was also responsible for leading the United States R&D organization to advance more than 100 active R&D projects across Dermatology, Ophthalmology, Gastroenterology, Oncology and Consumer Products. Dr. Kellen currently serves on the Advisory Boards of Paragon Biosciences and Castle Creek Pharmaceuticals.
Mr. Isaac B. Maresky – Chairman & CEO
Mr. Isaac Maresky is a serial entrepreneur and investment banking professional with hundreds of millions of dollars of financings and M&A experience. He co-founded another successful immunotherapy company alongside a veteran oncologist and cancer-vaccine pioneer, and led its go-public, subsequently joining Vaxil as apart of its restructuring efforts in an effort to advance its pipeline of innovative cancer therapies.
Mr. Maresky began his career at the Royal Bank of Canada in its Wealth Management Group known as Dominion Securities where he was the #1 performing intern of his year. Subsequently, he worked as an Investment Banking Analyst for a British Multinational Bank specializing in large M&A advisory.
Mr. Maresky then became a Principal with Sunel Securities investment bank, which invests private equity capital focused on value investing within the highest growth market segments. At Sunel, Mr. Maresky specialized in identifying and executing unique and attractive investment opportunities for the firm and its investors. In that regard, Mr. Maresky has visited, analyzed, and conducted in-depth diligence on assets and investment opportunities in several countries around the globe, subsequently leading financing rounds and privately structured deals.
Dr. Shawn Langer, M.D. – Director
Medical Doctor, University of Toronto
Dr. Shawn Langer brings over two decades of healthcare industry experience. Dr. Langer was Senior Partner at McKinsey & Company, where he was the leader of its Healthcare Private Equity Group.
During his 15 years with McKinsey & Company, Dr. Langer served healthcare clients across pharmaceuticals, biotechnology, medical devices, and healthcare services.
Most recently Dr. Langer has spent nearly 5 years investing in innovative healthcare companies in his capacity as a portfolio manager at healthcare private equity investment firm BMHS Investments.
Dr. Langer holds an MD from the University of Toronto.
Mr. Gadi Levin – CFO & Director
Masters of Science (MSc) in Accounting and B.Commerce | Chartered Accountant | MBA
Mr. Levin is an accountant with clinical-stage biotech experience. Mr. Levin served as Chief Financial Officer of Labstyle Innovations Ltd, a biotechnology company focused on diabetes. Mr. Levin served as the Vice President of Finance and Chief Financial Officer for two Israeli investment houses in the fields of private equity, hedge funds and real estate. More recently, Mr. Levin served as Chief Financial Officer of BriaCell Therapeutics Corp. developing an immunotherapy for late stage cancer patients.
Mr. Levin began his career at the former “Big Five” accounting firm Arthur Andersen, where he worked in the Cape Town, London, and Tel Aviv offices for nearly ten years. He holds a Bachelor of Commerce degree in Accounting and Information Systems from the University of the Cape Town, South Africa, and a Post-Grad in Accounting from the University of South Africa. He received his Chartered Accountant designation in South Africa and has an MBA from Bar Ilan University in Israel.